Xenon Pharmaceuticals Inc. — Q2 2015 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2015. Unless stated otherwise, financial figures are in U.S. dollars; income statement and cash-flow figures below are in millions.
Business context
Xenon is a clinical-stage biopharmaceutical company developing medicines for orphan and other indications, using its Extreme Genetics discovery platform. Revenue principally comes from collaboration agreements; the company reported no product sales revenue. Key partners include Teva and Genentech. Glybera, discovered using Xenon’s platform, is commercialized by licensee uniQure and its sublicensee.
Financial performance and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $4.046 | $5.298 | $8.056 | $10.299 |
| Operating expenses | $3.847 | $3.920 | $13.994 | $7.889 |
| Operating income (loss) | $0.199 | $1.378 | $(5.938) | $2.410 |
| Net income (loss) | $1.168 | $1.230 | $(7.988) | $2.603 |
| Net cash used in operating activities | Not provided separately | Not provided separately | $(7.971) | $(3.067) |
- At June 30, 2015, cash and cash equivalents were $64.346 million and marketable securities were $9.354 million, or $73.7 million combined. Cash and cash equivalents declined $7.680 million from December 31, 2014.
- Total assets were $76.527 million; total liabilities were $12.180 million. The company reported no outstanding debt.
- Six-month research and development expense rose to $7.096 million from $5.099 million, driven mainly by XEN801 development and other preclinical/discovery programs. General and administrative expense, including stock-based compensation, increased to $6.898 million from $2.790 million.
- Revenue fell year over year, principally because the Genentech upfront payment from its 2011 agreement had been fully recognized by December 2014, with lower partner research funding and currency effects also contributing.
Material changes, outlook and risks
- The Canadian dollar ceased to be Xenon’s functional currency on January 1, 2015; the U.S. dollar became its functional currency. Six-month foreign-exchange loss was $2.365 million, versus a loss of $0.085 million a year earlier. Xenon held $52.0 million of Canadian-dollar cash and marketable securities at June 30; management estimated a hypothetical 10% currency move would produce a $5.2 million gain or loss.
- Stock options granted before the IPO with Canadian-dollar exercise prices became liability-classified after the functional-currency change. Fair-value changes are recorded in earnings. A second-quarter fair-value recovery reduced stock-based compensation expense by $2.2 million; this contributed to the unusual negative $1.880 million G&A stock-compensation line for the quarter. The six-month period included a $2.7 million reclassification-related expense.
- On July 1, Teva and Xenon reported that TV-45070 did not significantly outperform placebo on knee osteoarthritis pain endpoints; they had no plans for further OA development at the time of the filing. Teva’s Phase 2b postherpetic-neuralgia trial continued, with results expected in the second half of 2016.
- Management expected significant expenses and operating losses for the foreseeable future, with R&D likely to remain the largest operating expense. It estimated available cash, securities and expected existing-collaboration research funding would support operations for at least 12–24 months, while cautioning that assumptions may prove wrong. Additional financing may be required thereafter.
- Xenon expected to file an IND-equivalent application for XEN801 in August 2015 and an IND for its Dravet syndrome program in 2016. These were expectations, not reported completed milestones.
- On August 7, 2015, Xenon entered a five-year, non-exclusive clinical-services priority-access agreement with Medpace, whose officer and director beneficially owns more than 5% of Xenon. Xenon committed to $7.0 million of services, including $1.7 million prepaid and another $1.3 million due during the remainder of 2015. Unused portions of the 2015 payments may be forfeited under specified conditions; additional commitment consequences apply if the minimum is not met.
- Management concluded disclosure controls and procedures were ineffective as of June 30, 2015, following a restatement of the March 2015 quarter. It reported no material changes in internal control over financial reporting during the quarter.
- Key risks include clinical and regulatory failure, dependence on collaborators and uncertain milestone income, future financing needs, foreign-exchange volatility, and Glybera’s uncertain commercialization and regulatory status. Xenon also disclosed that the EMA review of Glybera’s six-year follow-up data remained unresolved. No material legal proceedings were reported.
Most important facts for investors to verify
- The March 2015 quarterly restatement, its causes and remediation plan, and the status of disclosure-control improvements.
- Current cash runway against the company’s stated 12–24-month estimate, including actual spending and future collaboration funding.
- Further clinical progress and data for TV-45070 in postherpetic neuralgia, GDC-0276, XEN801 and the Dravet syndrome program, including whether expected filing dates were met.
- Teva and Genentech collaboration milestones, revenue recognition and remaining deferred revenue, and the commercial and regulatory outcome for Glybera.
- Canadian-dollar exposure and the quarterly earnings effects of liability-classified stock-option remeasurement.
- Medpace service utilization, payments and any related-party governance disclosures or minimum-commitment consequences.